Features

	Abbott Presents New Approach for Treating Attention-Deficit Hyperactivity Disorder Attention-Deficit Hyperactivity Disorder (ADHD), an ailment historically associated with childhood, persists into adulthood in more than two-thirds of cases. While medical treatment can improve the symptoms of ADHD, currently approved treatments often cause undesirable side effects, including increases in heart rate and blood pressure.
	Ensure Nutrition Education Network Helps Fight Malnutrition Malnutrition is a growing, global health problem. In Europe and the Middle East, 10 to 78 percent of hospital patients, particularly the elderly, suffer from the condition. The effects of malnutrition include disease complications, weakened immune function, increased morbidity and mortality, decreased quality of life, and increased cost of health care.
	Positive Results Published from First Bioabsorbable Drug-Eluting Stent Trial Abbott's bioabsorbable drug-eluting stent demonstrated excellent clinical safety in patients with coronary artery disease, according to results published in The Lancet. Watch an animation demonstrating how the stent works.
	FDA Approves Abbott's FreeStyle Navigator Continuous Glucose Monitoring System Our new FreeStyle Navigator system, now approved in the U.S. for people with diabetes, provides minute-by-minute information about glucose that can lead to quick, proactive diabetes management
	Faces of Heart Disease Abbott and the American Heart Association have partnered on an educational poster exhibit featuring inspirational stories of heart disease survivors.
	Abbott Targets Neuronal Nicotinic Receptors for Treatment of Pain and Cognition Based on a growing body of scientific knowledge related to neurotransmitters, the scientific community is now targeting neuronal nicotinic receptors (NNRs), found on nerve cells throughout the central nervous system, to treat a number of psychiatric and neurological disorders.
	Abbott Opens the Door to More Effective Biologic Treatments Through New Technology Abbott has opened up a whole new set of possibilities for drug development and biologic treatments that have the potential to more effectively treat individuals with cancer, autoimmune diseases and other complicated conditions.
	Abbott Again Named to Dow Jones Sustainability Index For the third year in a row, Abbott has been named to the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for its continued leadership in business, environmental and social performance.
	Abbott Responds to Devastating Earthquake in Peru Abbott responded quickly, working closely with relief partners Direct Relief International and AmeriCares, to provide critical nutritional and pharmaceutical products to those in affected areas. To date, a total of approximately $469,000 in product has been donated.
	Abbott Expands Commitment to Tanzania With Dedication of New Lab Abbott's Chairman and CEO Miles White participated in the dedication of the new Abbott Fund-supported laboratory at Mt. Meru Hospital in Tanzania, Africa.
	Environmental Responsibility Flourishes at Abbott Abbott is the first FORTUNE 500 company to go “carbon neutral” with its entire U.S. fleet of company sales vehicles. A solar panel installation in Temecula will power our vascular plant and a new Global Energy Policy is unveiled.
	Abbott Launches Institute Focused on Improving Care for Patients with Cardiac and Vascular Disease The Crossroads Institute, the first medical learning institute of its kind, advances the open exchange of information about cardiac and vascular care. The Institute features a teaching faculty of more than 100 worldwide experts providing the latest in cardiac and vascular care medical education.
	Abbott Sponsors "CoolGlobes" Exhibits in Chicago Similar to Chicago’s famous 1999 fiberglass "Cows on Parade" exhibit, "CoolGlobes: Hot Ideas for a Cooler Planet" is a public art exhibit that will feature 122 five-foot-tall globes created by local and international artists.
	m2000 Molecular Testing System Abbott's m2000 Molecular Testing System is meeting the demands of today's clinical laboratories. See how this technology is helping to improve medical care through earlier intervention.
	Abbott's Preclinical Oncology Pipeline May Help Advance Fight Against Cancer Robust preclinical data has shown that several compounds in Abbott's oncology pipeline may interfere with the vital processes of a cancer cell.
	Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico Abbott has officially opened Abbott Biotechnology Limited – the new, state-of-the-art biologics manufacturing facility in Puerto Rico that will support the long-term supply of a leading biologic agent, HUMIRA® (adalimumab).
	ZonePerfect and ABC's "Extreme Makeover: Home Edition" Honor Hero When ABC's "Extreme Makeover: Home Edition" rolled into Whitehall, a suburb of Columbus, Ohio, last November, Abbott's ZonePerfect joined M/I Homes and other Columbus-based businesses to give 9/11 hero Jason Thomas and his family a new home.
	Wall Street Journal: Abbott's Makeover Attracts Investors A recent Wall Street Journal article highlights Abbott CEO Miles White's strategic vision for the company and the impact it has had on investors.
	Abbott Builds "Green" With New Solar Panel Project in Germany The Abbott Diagnostics Wiesbaden-Delkenheim site recently completed a solar panel installation project expected to help Abbott address rising energy costs. Solar panels capture the sun’s energy, keeping energy expenses down while reducing carbon dioxide emissions, which are commonly linked to global warming.
	Abbott and the Magic Johnson Foundation Recognize World AIDS Day with Launch of New Program On World AIDS Day Abbott and the Magic Johnson Foundation announced the launch of the "I Stand With Magic: Campaign to End Black AIDS" program.
	HUMIRA Wins Expanded Approval in Psoriatic Arthritis Indication Based on data from an extension of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), the U.S. Food and Drug Administration has approved an expanded indication for Abbott's HUMIRA that now includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA)
	Similac Moms Alliance Parenting Network U.S. Olympic Gold Medalist and New Mom Summer Sanders Becomes First Member of Similac Moms Alliance Parenting Network
	Abbott Animation: Vulnerable Plaque Read a recent New York Times article about Vulnerable Plaque - plaques that can build up in a coronary artery, possibly leading to a heart attack. Learn why Abbott science is investigating Vulnerable Plaque and watch a short video explaining how these plaques can eventually rupture.